A scoring system for prescribing fidaxomicin in Clostridium diffícile infection
Enferm Infecc Microbiol Clin (Engl Ed). 2018 Jan;36(1):34-37.
doi: 10.1016/j.eimc.2016.07.013.
Epub 2016 Sep 3.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, España. Electronic address: mjesus.vivancos@gmail.com.
- 2 Servicio de Urgencias, Hospital 12 de Octubre, Madrid, España.
- 3 Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid, España.
- 4 Servicio de Microbiología, Hospital Ramón y Cajal, Madrid, España.
- 5 Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, España.
Abstract
Recurrences of Clostridium difficile infections lead to hospital readmissions and high costs, in addition to the suffering and frustration for the patients. Fidaxomicin has recently been introduced as a new antibiotic that has been shown to significantly reduce the recurrence of this infection. Despite this superiority, its high cost has led to very restrictive policies in its use, as such that many institutions only use it in patients with multiple recurrences. While waiting for new predictive clinical tools, we propose the development of scoring systems that allow the more high-risk patients to be treated earlier.
Keywords:
Clostridium difficile; Fidaxomicin; Fidaxomicina; Recurrences; Recurrencia.
Copyright © 2016 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.
MeSH terms
-
Aged, 80 and over
-
Anti-Bacterial Agents / therapeutic use*
-
Clostridium Infections / drug therapy*
-
Female
-
Fidaxomicin / therapeutic use*
-
Humans
-
Male
-
Patient Selection
-
Recurrence
-
Risk Assessment
Substances
-
Anti-Bacterial Agents
-
Fidaxomicin